tiprankstipranks
Pharming Novartis announces first commercial shipments of Joenja in U.S.
The Fly

Pharming Novartis announces first commercial shipments of Joenja in U.S.

Pharming (PHAR) announced the first commercial shipments of Joenja to patients in the United States. Joenja, an oral, selective PI3Kdelta inhibitor, is the first and only treatment approved in the U.S. for activated phosphoinositide 3-kinase delta syndrome, or APDS, a rare and progressive primary immunodeficiency, in adult and pediatric patients 12 years of age and older. Under the terms of Pharming’s 2019 exclusive license agreement with Novartis (NVS) for leniolisib, the corresponding first commercial sale of Joenja triggers a $10M milestone payment by Pharming to Novartis.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on PHAR:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles